EHC Quote, Financials, Valuation and Earnings

Kindly MD has a net margin of 8.61% compared to Encompass Health's net margin of -156.54%. Encompass Health's return on equity of 17.79% beat Kindly MD's return on equity of -201.03%.

Encompass Health has a consensus price target of $117.25, signalling upside risk potential of 19.69%. On the other hand Kindly MD has an analysts' consensus of -- which suggests that it could fall by --. Given that Encompass Health has higher upside potential than Kindly MD, analysts believe Encompass Health is more attractive than Kindly MD.

Encompass Health has a beta of 0.882, which suggesting that the stock is 11.77% less volatile than S&P 500. In comparison Kindly MD has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Encompass Health has a quarterly dividend of $0.17 per share corresponding to a yield of 0.67%. Kindly MD offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Encompass Health pays 13.78% of its earnings as a dividend. Kindly MD pays out -- of its earnings as a dividend. Encompass Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Encompass Health quarterly revenues are $1.4B, which are larger than Kindly MD quarterly revenues of $647.9K. Encompass Health's net income of $120.9M is higher than Kindly MD's net income of -$1M. Notably, Encompass Health's price-to-earnings ratio is 21.96x while Kindly MD's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Encompass Health is 1.86x versus 3.11x for Kindly MD. Usually stocks with elevated PS ratios are considered overvalued.

Pediatrix Medical Group has a net margin of 8.61% compared to Encompass Health's net margin of 6.07%. Encompass Health's return on equity of 17.79% beat Pediatrix Medical Group's return on equity of -12.67%.

Encompass Health has a consensus price target of $117.25, signalling upside risk potential of 19.69%. On the other hand Pediatrix Medical Group has an analysts' consensus of $18.36 which suggests that it could grow by 35.88%. Given that Pediatrix Medical Group has higher upside potential than Encompass Health, analysts believe Pediatrix Medical Group is more attractive than Encompass Health.

Encompass Health has a beta of 0.882, which suggesting that the stock is 11.77% less volatile than S&P 500. In comparison Pediatrix Medical Group has a beta of 1.325, suggesting its more volatile than the S&P 500 by 32.466%.

Encompass Health has a quarterly dividend of $0.17 per share corresponding to a yield of 0.67%. Pediatrix Medical Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Encompass Health pays 13.78% of its earnings as a dividend. Pediatrix Medical Group pays out -- of its earnings as a dividend. Encompass Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Encompass Health quarterly revenues are $1.4B, which are larger than Pediatrix Medical Group quarterly revenues of $502.4M. Encompass Health's net income of $120.9M is higher than Pediatrix Medical Group's net income of $30.5M. Notably, Encompass Health's price-to-earnings ratio is 21.96x while Pediatrix Medical Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Encompass Health is 1.86x versus 0.56x for Pediatrix Medical Group. Usually stocks with elevated PS ratios are considered overvalued.

The Oncology Institute has a net margin of 8.61% compared to Encompass Health's net margin of -13.15%. Encompass Health's return on equity of 17.79% beat The Oncology Institute's return on equity of -220.55%.

Encompass Health has a consensus price target of $117.25, signalling upside risk potential of 19.69%. On the other hand The Oncology Institute has an analysts' consensus of -- which suggests that it could grow by 48.15%. Given that The Oncology Institute has higher upside potential than Encompass Health, analysts believe The Oncology Institute is more attractive than Encompass Health.

Encompass Health has a beta of 0.882, which suggesting that the stock is 11.77% less volatile than S&P 500. In comparison The Oncology Institute has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Encompass Health has a quarterly dividend of $0.17 per share corresponding to a yield of 0.67%. The Oncology Institute offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Encompass Health pays 13.78% of its earnings as a dividend. The Oncology Institute pays out -- of its earnings as a dividend. Encompass Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Encompass Health quarterly revenues are $1.4B, which are larger than The Oncology Institute quarterly revenues of $100.3M. Encompass Health's net income of $120.9M is higher than The Oncology Institute's net income of -$13.2M. Notably, Encompass Health's price-to-earnings ratio is 21.96x while The Oncology Institute's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Encompass Health is 1.86x versus 0.26x for The Oncology Institute. Usually stocks with elevated PS ratios are considered overvalued.

US Physical Therapy has a net margin of 8.61% compared to Encompass Health's net margin of 4.12%. Encompass Health's return on equity of 17.79% beat US Physical Therapy's return on equity of 3.86%.

Encompass Health has a consensus price target of $117.25, signalling upside risk potential of 19.69%. On the other hand US Physical Therapy has an analysts' consensus of $108.33 which suggests that it could grow by 61.45%. Given that US Physical Therapy has higher upside potential than Encompass Health, analysts believe US Physical Therapy is more attractive than Encompass Health.

Encompass Health has a beta of 0.882, which suggesting that the stock is 11.77% less volatile than S&P 500. In comparison US Physical Therapy has a beta of 1.376, suggesting its more volatile than the S&P 500 by 37.634%.

Encompass Health has a quarterly dividend of $0.17 per share corresponding to a yield of 0.67%. US Physical Therapy offers a yield of 2.64% to investors and pays a quarterly dividend of $0.45 per share. Encompass Health pays 13.78% of its earnings as a dividend. US Physical Therapy pays out 100.3% of its earnings as a dividend. Encompass Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but US Physical Therapy's is not.

Encompass Health quarterly revenues are $1.4B, which are larger than US Physical Therapy quarterly revenues of $180.4M. Encompass Health's net income of $120.9M is higher than US Physical Therapy's net income of $7.4M. Notably, Encompass Health's price-to-earnings ratio is 21.96x while US Physical Therapy's PE ratio is 36.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Encompass Health is 1.86x versus 1.51x for US Physical Therapy. Usually stocks with elevated PS ratios are considered overvalued.